Structure Therapeutics In... (GPCR)
| Bid | 20.99 |
| Market Cap | 414.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -122.53M |
| EPS (ttm) | -2.34 |
| PE Ratio (ttm) | -9.27 |
| Forward PE | -12.66 |
| Analyst | Buy |
| Ask | 21.63 |
| Volume | 5,617,082 |
| Avg. Volume (20D) | 846,913 |
| Open | 21.26 |
| Previous Close | 18.53 |
| Day's Range | 19.74 - 24.17 |
| 52-Week Range | 13.22 - 62.74 |
| Beta | -1.46 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral sma...
Analyst Forecast
According to 9 analyst ratings, the average rating for GPCR stock is "Buy." The 12-month stock price forecast is $83.5, which is an increase of 284.97% from the latest price.
Stock Forecasts
4 weeks ago · seekingalpha.com
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 CandidateStructure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, al...
